Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay

Gala­pa­gos is as­sess­ing “var­i­ous strate­gic op­tions” with Jy­s­e­le­ca, the JAK in­hibitor that once in­spired block­buster pro­jec­tions but re­peat­ed­ly dis­ap­point­ed. The Bel­gian biotech at­trib­uted the move

While many adolescents and young adults (AYA) with cancer died in their preferred locations, about 30% who wanted to die at home were unable to